drugset / Trial / NCT06203977
Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Phase 1
Recruiting
200 enrolled
Hamilton Health Sciences Corporation
Hamilton Academic Health Sciences Organization · collabSt. Joseph's Health Care London · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Timeline
- Start
- 2024-11-15
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Colchicine | Small molecule | 0.3 mg | — |
| Comparator | Colchicine | Small molecule | 0.6 mg | — |